首页> 美国卫生研究院文献>The Cochrane Database of Systematic Reviews >Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

【2h】

Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

机译：每日一次长效β2受体激动剂和长效毒蕈碱拮抗剂在吸入器与安慰剂的组合中治疗慢性阻塞性肺疾病

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:To assess the effects of single‐inhaler LABA/LAMA combinations versus placebo on clinically meaningful outcomes in patients with stable COPD.

机译：这是Cochrane评估（干预）的方案。目的如下：评估单吸入剂LABA / LAMA与安慰剂的组合对稳定COPD患者具有临床意义的结果的影响。

著录项

期刊名称 The Cochrane Database of Systematic Reviews
作者
Usman Maqsood; David JW Evans; Terence N Ho; Karen Palmer; Fiona JR Eccles; Mohammed Munavvar; Iain Crossingham;
展开▼
作者单位

展开▼
年(卷),期 -1(2018),1
年度 -1
页码 CD012930
总页数 13
原文格式 PDF
正文语种
中图分类基础医学;
关键词

相似文献

外文文献
中文文献
专利

1. Cost Effectiveness of the Long-Acting P2-Adrenergic Agonist (L ABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LAB A/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal [J] . M. Reza Maleki-Yazdi, Mathieu Molimard, Dorothy L. Keininger, Applied health economics and health policy . 2016,第5期

机译：长效P2-肾上腺素激动剂（L ABA）/长效毒蕈碱拮抗药双重支气管扩张药Indacaterol / Glycopyrronium与LAB A /吸入糖皮质激素联合沙美特罗/氟替卡松在慢性阻塞性肺部疾病患者中的成本效益比较：分析法国，意大利和葡萄牙
2. Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers [J] . David Singer, Lindsay GS Bengtson, Caitlin Elliott, International Journal of Chronic Obstructive Pulmonary Disease . 2020,第1期

机译：医疗保健资源利用率，慢性阻塞性肺病患者的慢性阻塞性肺病患者中的再服用，用软雾与干粉吸入器
3. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial [J] . Vestbo Jorgen, Papi Alberto, Corradi Massimo, The Lancet . 2017,第10082期

机译：单一吸入器外列三倍治疗与长效毒蕈碱拮抗剂治疗慢性阻塞性肺病（三位一体）：双盲，平行组，随机对照试验
4. SYNTHESIS OF VEDACLIDINE-14C (+)-TARTRATE, A CENTRALLY ACTING MUSCARINIC AGONIST AND ITS USE IN QWBA STUDIES IN RATS [C] . William J. Wheeler, Douglas D. OBannon, Sylvia H. Chay, International Symposium on the Synthesis and Applications of Isotopes and Isotopically Labelled Compounds . 2004

机译：Vedaclidine-14c（+） - 酒石酸酯，一种中央作用毒蕈碱激动剂及其在大鼠QWBA研究中的用途
5. Addition of leukotriene receptor antagonists versus long acting beta agonists to inhaled corticosteroid therapy for asthma treatment in older adults: A retrospective data analysis of effectiveness, safety and cost. [D] . Altawalbeh, Shoroq Mahmoud. 2015

机译：在吸入性糖皮质激素治疗中，将白三烯受体拮抗剂与长效β激动剂相比，用于老年人的哮喘治疗：有效性，安全性和成本的回顾性数据分析。
6. Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease [O] . Usman Maqsood, Terence N Ho, Karen Palmer, -1

机译：每日一次长效β2受体激动剂和长效毒蕈碱拮抗剂在吸入器与安慰剂的组合中治疗慢性阻塞性肺疾病
7. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease [O] . Usman Maqsood, Terence N Ho, Karen Palmer, 2019

机译：曾经每天长效的β2-激动剂和长效的毒蕈碱拮抗剂，在慢性阻塞性肺病的组合吸入者与安慰剂中

Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅